Compumedics LimitedASX: CMP

Somfit D FDA

· Issued by Compumedics Limited

Filed with ASX · · 2 pages · English

Summary by 6ix AI

Compumedics Limited announced that the U.S. Food and Drug Administration has granted clearance for its Somfit®D device, which is a single-use Home Sleep Testing solution, effectively doubling the addressable U.S. market for the product. The clearance allows Compumedics to tap into a significant annual market for home sleep testing, which has been rapidly shifting towards single-use devices. The company aims to leverage its existing U.S. salesforce and established relationships to commence immediate commercialization of Somfit®D. Compumedics reaffirms its revenue guidance for the upcoming fiscal year, anticipating substantial contributions from the new device as market adoption increases.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Compumedics Limited on 6ix

Earlier from Compumedics

Later from Compumedics

All Compumedics news releases